Stay updated on PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo

Sign up to get notified when there's something new on the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page.
Latest website image capture
Clouds background image

Latest updates to the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page

  1. Check
    2 days ago
    Change Detected
    Summary
    An NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence.”
    Difference
    1%
    Check dated 2026-10-25T15:39:54.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The footer’s site revision number changes from v3.7.1 to v3.7.2; the page still displays a 403 error.
    Difference
    0.2%
    Check dated 2026-10-18T22:16:19.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer’s site revision changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T21:53:27.000Z thumbnail image
  4. Check
    36 days ago
    Change Detected
    Summary
    Access to the study record now returns a 403 Forbidden page, with the site chrome visible but no study details. This indicates the page loads an access-denied response rather than the expected content.
    Difference
    19%
    Check dated 2026-09-20T22:24:10.000Z thumbnail image
  5. Check
    57 days ago
    Change Detected
    Summary
    The page now includes a new line '2023 ( U.S. NIH Grant/Contract )' under Other Study ID Numbers, and the page revision has been updated from v3.6.5 to v3.6.6 (the previous revision line was removed).
    Difference
    0.1%
    Check dated 2026-08-30T21:42:35.000Z thumbnail image
  6. Check
    72 days ago
    Change Detected
    Summary
    Plain Language Summary was removed from the study page, eliminating the layperson-friendly overview of the trial and its objectives.
    Difference
    0.0%
    Check dated 2026-08-16T15:33:55.000Z thumbnail image

Stay in the know with updates to PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo

Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page.